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CAM use among overweight and obese persons
with radiographic knee osteoarthritis
Kate L Lapane1*, Shibing Yang2, Rachel Jawahar2, Timothy McAlindon3 and Charles B Eaton4,5
Abstract
Background: Obesity is associated with knee pain and is an independent predictor of incident knee osteoarthritis
(OA); increased pain with movement often leads patients to adopt sedentary lifestyles to avoid pain. Detailed
descriptions of pain management strategies by body mass index (BMI) level among OA patients are lacking. The
objectives were to describe complementary and alternative medicine (CAM) and conventional medication use by
BMI level and identify correlates of CAM use by BMI level.
Methods: Using Osteoarthritis Initiative baseline data, 2,675 patients with radiographic tibiofemoral OA in at least
one knee were identified. Use of CAM therapies and conventional medications was determined by interviewers.
Potential correlates included SF-12, CES-D, Western Ontario and McMaster Universities Osteoarthritis Index, and
Knee injury and Osteoarthritis Outcome Score quality of life. Multinomial logistic regression models adjusting for
sociodemographic and clinical factors provided estimates of the association between BMI levels and treatment use; binary
logistic regression identified correlates of CAM use.
Results: BMI was inversely associated with CAM use (45% users had BMI ≥35 kg/m2; 54% had BMI <25 kg/m2), but
positively associated with conventional medication use (54% users had BMI ≥35 kg/m2; 35.1% had BMI <25 kg/m2).
Those with BMI ≥30 kg/m2 were less likely to use CAM alone or in combination with conventional medications when
compared to patients with BMI <25 kg/m2.
Conclusions: CAM use is common among people with knee OA but is inversely associated with BMI. Understanding
ways to further symptom management in OA among overweight and obese patients is warranted.
Keywords: Knee osteoarthritis, Obesity, Pain, Complementary and alternative medicine
Background
Obesity is an independent predictor of incident knee osteo-
arthritis (OA) [1]. Both weight gain and malalignment are
also associated with increased pain and functional loss [2].
OA patients with body mass index (BMI) ≥ 35 kg/m2 often
experience increased pain due to significant increases in
joint stress and load forces on the knees [3]. Obesity is a
modifiable risk factor for the development and treatment
of knee pain [4]. In two major trials [5,6], people random-
ized to intensive lifestyle interventions which focused on
exercise and weight loss demonstrated improvements in
pain and physical function relative to controls. Interven-
tions including both exercise and weight loss were more
successful than those using either approach alone [7].
Diffusing interventions is challenging because increased
pain with movement often leads patients to adopt seden-
tary lifestyles to avoid pain, which leads to more weight
gain, pain, and disability.
OA is a chronic disease with no cure so patients often
treat pain with conventional medications or therapies [8]
and complementary and alternative medicines (CAM)
[9,10]. Glucosamine [11] and acupuncture [12] do relieve
symptoms among OA patients. Obese adults are less likely
to use CAM overall [13], but detailed CAM practices
among people with higher BMI are unknown.
The Osteoarthritis Initiative (OAI) provides the oppor-
tunity to address this gap in the literature. The OAI
is a multi-center, prospective observational study which
examines the natural history of and identifies risk factors
for incidence and progression of knee OA [14]. The OAI
is a unique data source because it provides a population
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with radiographic confirmation of OA and detailed
assessments of knee-specific pain, quality of life, and
functioning indicators using standardized instruments.
The study purpose was twofold: 1) to describe differ-
ences in treatment approaches to manage symptoms of
knee OA by level of BMI; and 2) to evaluate the extent
to which sociodemographic and clinical correlates of
CAM use differed by BMI.
Methods
The University of Massachusetts Medical School Institu-
tional Review Board reviewed and approved the protocol
for this study. Because publicly-available data were used for
this study, the Institutional Review Board waived the need
for documentation of informed consent from participants.
We used publicly available data from the OAI (http://
www.oai.ucsf.edu/) (#AllClinical00, V0.2.2). The OAI
began recruiting in 2004 and engaged 4,796 participants
aged 45 to 79 years. At baseline, each participant under-
went 3.0 Tesla MRI examinations of the knee and
provided blood samples, and each clinical site had
readers (trained through didactic and interactive web-
based methods) assess fixed flexion knee x-rays for
osteophytes and joint space narrowing. Eligibility was
restricted to those without severe joint space narrowing
in both knees. The participants were followed annually
for the development or progression of knee OA. We in-
cluded 2,679 individuals with radiographic tibiofemoral
knee OA (e.g. OARSI atlas osteophyte grade I–III) [15]
in at least one knee at baseline and excluded 4 participants
with missing height and/or weight measured using stan-
dardized methods (n = 2,675). Participants were classified
into four categories: BMI less than 25 kg/m2, BMI be-
tween 25 and less than 30 kg/m2 (overweight), BMI from
30 to less than 35 kg/m2 (obese), and BMI of at least
35 kg/m2 (severe obesity) [16].
Classification of use of CAM and conventional medications
Complementary and alternative therapies were defined
as [9]: 1) alternative medical systems (e.g. homeopathy,
acupuncture); 2) mind-body interventions (e.g. pilates,
spiritual activities, relaxation therapy); 3) manipulation
Table 1 Sociodemographic and descriptive characteristics of participants with radiographic-confirmed knee OA by BMI
level (N = 2,675)
BMI ≥ 35 kg/m2 BMI between 30 and <35 kg/m2 BMI between 25 and <30 kg/m2 BMI < 25 kg/m2
(n = 364) (n = 804) (n = 1,042) (n = 465)
Percentage
Age (years): ≥ 65 27.5 39.6 48.9 49.9
Women 69.0 57.8 50.3 69.0
Race/ethnicity: White 58.8 72.7 82.7 89.3
African American 38.7 24.3 13.3 6.5
Latino 1.1 0.8 1.8 1.7
Other 1.4 2.2 2.1 2.6
Education:≥College graduate 40.8 50.4 59.9 66.2
Some college 36.9 28.2 22.7 21.3
≤ High school 22.4 21.3 17.5 12.6
Income ($):>100,000 15.6 20.1 24.3 22.4
50 k–100 k 29.9 35.8 36.2 40.0
25 k–50 k 31.4 27.9 26.7 24.0
≤ 25,000 23.1 16.2 12.8 13.7
Married/partnered 53.4 62.9 68.8 73.9
Working (for pay) 65.1 61.1 57.0 52.3
Health insurance 91.6 96.1 98.3 98.5
Insurance covers prescriptions 83.3 87.5 87.9 86.7
CES-D > 16 (Depressed) 15.9 10.1 7.2 7.5
Mean (standard deviation)
Weight at age 25 (kg) 71.7 (14.9) 70.8 (14.7) 67.7 (13.1) 60.7 (10.1)
SF-12* Mental summary 52.3 (9.5) 53.4 (8.6) 54.7 (7.5) 53.9 (7.9)
SF-12* Physical summary 42.4 (10.6) 46.8 (9.3) 48.6 (9.0) 50.9 (8.0)
*SF-12 (range: 0 to 100 with higher scores indicating better health).
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and body-based methods (e.g. massage and chiropractic);
4) energy therapies (e.g. copper bracelets); 5) topical
biologically based therapies including rubs (e.g. tiger
balm); 6) biologically based diet; or 7) biologically based
supplements (e.g. glucosamine, chondroitin). CAM use
for the past year was determined by a series of questions
including, “During the past 6 months, did you use the
following health supplements for joint pain or arthritis?”
Conventional medication use was captured in baseline
surveys as self-reported use. A four-level outcome variable
was created: CAM use only, conventional medication use
only, both, and no use.
Potential correlates
Treatment of OA is influenced by sociodemographic
indicators, overall measures of mental and physical well-
being, and clinical indices of OA. We anticipated CAM
use to be different by age group [17], gender [18], race/
ethnicity [19,20], education [21], annual household
income, employment status, and health insurance status.
Physical and mental health status were assessed by the
12-item Medical Outcomes Study Short Form (SF-12)
[22] (range from 0 to 100, with higher scores indicating
better health status). Depression status was measured
with the CES-D Scale (≥16) [23].
A pain score of 20 in the Western Ontario and
McMaster Universities (WOMAC) Osteoarthritis Index
(Version LK 3.1) [24,25] indicated the worst pain (range
0 to 20). Knee-related quality of life was measured by
the Knee injury and Osteoarthritis Outcome Score
(KOOS) by calculating a summary score ranging from 0
to 100 (range: 0 (extreme symptoms) to 100 (no symp-
toms)) [26]. The knee with worse measures was used
in the analysis. Walking ability and endurance were
measured by a 20-meter walk, averaged over two trials
[27]. The chair stand test directly assessed leg strength and
knee function and duration of time (seconds) needed to
stand up and sit down five times as quickly as possible [28].
Participants were classified by x-ray joint space nar-
rowing as determined by OARSI atlas grade on a fixed
flexion radiograph of the knee with the worst measure.
Multiple-joint OA symptoms were measured with self-
reported information at baseline: low back pain in previous
30 days, OA in hand, hip symptoms, and hip replacement.
Information on previous history of knee injury or surgery
was also collected.
Analytic approach
A multivariable multinomial logistic regression model
was developed to estimate the association between BMI
level and CAM/conventional treatment use after adjusting
Table 2 Clinical characteristics of participants with radiographic-confirmed knee OA by BMI level (N = 2,675)
BMI ≥ 35 kg/m2 BMI between 30
and <35 kg/m2
BMI between 25
and <30 kg/m2
BMI < 25 kg/m2
(n = 364) (n = 804) (n = 1,042) (n = 465)
Symptoms Mean (standard deviation)
WOMAC*–Pain 6.1 (4.7) 4.4 (4.0) 3.7 (3.6) 2.8 (3.3)
KOOS*–QOL 53.5 (25.1) 60.3 (22.5) 64.2 (22.5) 69.5 (21.0)
Function and performance
Isometric strength/chair stands (seconds) 13.1 (4.4) 12.1 (4.0) 11.6 (3.8) 10.6 (3.0)
20-meter walk (seconds) 17.5 (4.0) 16.3 (3.1) 15.5 (2.8) 15.1 (2.6)
Joint space narrowing: x-ray evidence of knee severity Percentage
OARSI grade 0 (normal) 26.9 27.5 31.0 35.1
OARSI grade 1–2 (narrowed) 52.2 51.5 46.6 48.2
OARSI grade 3 (severe) 20.9 21.0 22.4 16.8
Multi-joint osteoarthritis
Bilateral knee OA 68.4 66.0 60.9 53.3
Any back pain (30 days) 66.5 56.7 56.3 59.6
Hand osteoarthritis 15.8 17.6 18.1 22.5
Hip symptoms (12 months) 30.9 24.4 23.9 21.2
Total hip replacement 0.8 2.5 1.8 1.9
History
History of knee injury 52.8 46.8 47.2 46.0
History of knee surgery 27.6 29.0 31.9 26.9
*WOMAC score ranges from 0 to 20, with 20 indicating worst pain. KOOS score ranges from 0 (extreme symptoms) to 100 (no symptoms).
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for sociodemographic and clinical characteristics. We used
a multinomial logistic regression model because the out-
come variable of interest was four levels: 1) use of CAM
only; 2) use of conventional medications only; 3) use of
both; and 4) use of neither. The models produced odds
ratios (ORs) and corresponding 95% confidence intervals
(CIs). Multicollinearity among the variables of interest was
assessed and ruled out by evaluating a correlation matrix
before the modeling process and then by carefully evaluat-
ing the standard errors as new variables were introduced
into the model. Odds ratios for the KOOS- QOL scale
and chair stand test were calculated as one standard
deviation change in each variable. To determine correlates
of CAM use stratified by BMI levels, we created separate
logistic regression models for each BMI level. The out-
come variable in these models was use of CAM (yes/no).
Results
Table 1 shows sociodemographic measures by BMI level.
Most participants with BMI ≥ 35 kg/m2 were women (69.0%)
and were younger than participants with BMI < 25 kg/m2
(27.5% over 65 years of age vs. 49.9%). Seventy-four percent
Table 3 CAM use among participants with radiographic-confirmed knee OA by BMI level (N = 2,675)
Categorya BMI ≥ 35 kg/m2 BMI between 30
and <35 kg/m2
BMI between 25
and <30 kg/m2
BMI < 25 kg/m2
(n = 364) (n = 804) (n = 1,042) (n = 465)
Percentage
Alternative medical systems 1.1 0.8 1.1 2.2
Acupuncture 0.3 0.5 0.5 1.5
Acupressure 0.3 0 0.3 0.4
Chelation therapy 0 0 0 0
Folk medicine 0 0 0 0
Homeopathy 0.3 0 0.4 0.2
Ayurveda/biofeedback/energy healing/ hypnosis/naturopathy 0.8 0.3 0.3 0.4
Mind-body interventions 11.8 10.8 8.4 14.6
Yoga/Tai Chi/Chi Gong/Pilates 3.9 4.5 5.3 10.3
Relaxation therapy, meditation, breathing 3.6 4.6 2.5 3.9
Spiritual activities 7.1 4.4 2.7 3.2
Manipulation and body-based methods 5.5 5.7 4.9 5.0
Chiropractic 4.7 4.6 4.1 3.9
Massage 2.5 1.7 1.6 1.7
Energy therapies (Copper bracelets or magnets) 5.8 3.1 3.2 3.4
Biologically based therapies: topical agent 18.1 15.1 11.9 9.7
Rubs, lotions, liniments, creams or oils(tiger balm/horse liniment) 17.6 14.8 11.7 9.7
Capsaicin 1.9 1.7 1.6 1.3
Biologically based therapies: diet 2.2 0.8 0.9 1.7
Biologically based therapies: supplements 23.4 29.2 32.9 41.3
Herbs 1.7 1.9 1.2 2.2
Vitamins/minerals (nearly every day) 5.2 6.0 6.3 7.5
Glucosamine (nearly every day) 19.8 24.5 28.8 36.6
Methylsulfonylmethane (MSM) 3.6 6.0 6.0 6.5
S-adenosylmethionine (SAMe) 0.0 0.3 0.7 0.9
Chondroitin (nearly every day) 19.0 22.1 26.5 32.5
Distributionb of CAM use:
One 28.3 32.0 33.0 35.1
Two 11.3 9.8 9.1 14.4
Three or more 5.0 4.2 3.5 4.3
aAs defined by the National Center for Complementary and Alternative Medicine;
bNumber of CAM use was defined on basis of the broader categories.
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of participants with BMI < 25 kg/m2 were married
whereas 53.4% of those with BMI ≥ 35 kg/m2 were.
Sixty-six percent of participants with BMI < 25 kg/m2
were at least a college graduate whereas 41% of those
with BMI ≥ 35 kg/m2 had.
Table 2 shows clinical measures by BMI level. The
mean KOOS QOL score for participants with BMI <
25 kg/m2 was 69.5 (standard deviation: 21.0) and it was
53.5 in participants with BMI ≥ 35 kg/m2 (standard
deviation: 25.1). The mean WOMAC pain scores was
6.1 in participants with BMI ≥ 35 kg/m2 (standard devi-
ation: 4.7) and 2.8 in participants with BMI < 25 kg/m2
(standard deviation: 3.3). Severe joint space narrowing
was 20.9% in participants with BMI ≥ 35 kg/m2 and
16.8% in participants with BMI < 25 kg/m2.
Table 3 shows specific CAM therapies stratified by
BMI level. Fifty percent of participants with BMI <
25 kg/m2 and 39.6% of participants with BMI ≥ 35 kg/m2
Table 4 Conventional medication use among participants with radiographic-confirmed knee OA by BMI level (N = 2,675)
Category BMI ≥ 35 kg/m2 BMI between 30
and <35 kg/m2
BMI between 25
and <30 kg/ m2
BMI < 25 kg/m2
(n = 364) (n = 804) (n = 1,042) (n = 465)
Percentage
Acetaminophen 18.1 11.4 9.7 8.8
Any NSAIDs 35.4 26.9 24.2 23.2
Over-the-counter NSAIDs 27.8 21.4 19.7 18.1
Prescription NSAIDs 12.4 7.8 6.2 6.5
COX-2 Inhibitors 9.9 8.5 8.7 6.9
Acetaminophen or NSAIDs 45.9 34.1 29.9 28.4
Doxycycline 0.3 0.4 0.5 0.0
Narcotics 5.8 3.5 1.4 2.2
Knee injectionsa 4.7 4.5 3.4 2.6
Hyaluronic acid 1.1 1.1 1.2 0.9
Steroids 4.4 3.7 2.0 1.3
Distribution of conventional medications:b
One 34.6 29.5 27.1 26.7
Two 13.5 9.1 7.9 6.9
Three or more 5.5 3.0 2.1 1.5
aThe sum of percentages of hyaluronic acid and steroid injections may not be equal to the total percentage of knee injections because participants may use both
hyaluronic acid and steroids, or use injections other than hyaluronic acid and steroids.
bNumber of conventional medication used was based on the first seven items in this table.
Figure 1 Distribution of concomitant conventional medication use among CAM users, stratified by BMI level.
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used one or two CAM therapies, either alone or with
conventional medication. Although more participants
with BMI < 25 kg/m2 used CAM overall relative to over-
weight and obese participants, differences by specific
CAM type exist. Energy therapies were more common
amongst overweight and obese participants (5.8% ≥
35 kg/m2 versus 3.4% BMI < 25 kg/m2) as were topical
therapies (18.1% ≥ 35 kg/m2 versus 9.7% BMI < 25 kg/m2).
Table 4, which shows specific conventional therapies by
BMI level, indicates the reverse is true for conventional
medications; 8.4% of participants with BMI < 25 kg/m2
and 19% of participants with BMI ≥ 35 kg/m2 reported at
least two conventional medications. Doxycycline use was
very low overall.
Figure 1 shows CAM use and types of concurrent
conventional medication use by BMI level. The most
commonly used concurrent conventional therapies amongst
all BMI groups was acetaminophen and/or non-steroidal
anti-inflammatory agents (NSAIDs) which were over-the-
counter or prescription.
Table 5 shows the association between CAM and con-
ventional treatment use and BMI level. Both participants
with BMI between 30 and 35 kg/m2 and participants
with BMI between 25 and 30 kg/m2 reported using
CAM with conventional medications less often than
participants with BMI < 25 kg/m2 (adjusted odds ratio
(AOR): 0.38, 95% CI: 0.20-0.73 for participants with BMI
between 30 and 35 kg/m2; AOR: 0.35, 95% CI: 0.19-0.65
for participants with BMI between 25 and 30 kg/m2).
Table 6 shows correlates of any CAM use by BMI
level. Participants with BMI ≥ 35 kg/m2 and over 65 years
of age were more likely to use CAM than younger
participants (AOR: 2.79, 95% CI: 1.53-5.09). Black
persons with BMI between 25 and 30 kg/m2 were less
likely to report CAM use compared to white persons
(AOR: 0.36, 95% CI: 0.23-0.58). Among persons with
BMI of 25 to 30 and 30 to 35 kg/m2, having a college
degree or higher was associated with CAM use, relative
to a high school education or less (AOR: 1.71 and 1.84,
respectively).
Discussion
Persons with BMI levels of at least 25 kg/m2 had greater
prevalence of severe joint space narrowing, greater pain,
Table 5 Association between BMI level and treatment approaches among people with knee OA
Treatment use CAM only Conventional medications only Both
Odds ratios
(95% Confidence intervals)
BMI ≥ 35 kg/m2 versus referent group BMI <25 kg/m2
Crude 0.48 2.51 1.38
(0.31–0.73) (1.55–4.07) (0.94–2.04)
Socio-demographic adjusted† 0.50 1.69 1.16
(0.28–0.91) (0.81–3.53) (0.65–2.09)
Socio-demographic and clinical characteristic adjusted†† 0.47 1.13 0.55
(0.24–0.92) (0.47–2.70) (0.27–1.12)
BMI between 30 and <35 kg/m2 versus referent group BMI <25 kg/m2
Crude 0.70 1.71 0.94
(0.50–0.98) (1.09–2.68) (0.66–1.34)
Socio-demographic adjusted† 0.71 1.29 0.71
(0.43–1.17) (0.65–2.57) (0.41–1.22)
Socio-demographic and clinical characteristic adjusted†† 0.59 0.84 0.38
(0.34–1.04) (0.37–1.88) (0.20–0.73)
BMI between 25 and <30 kg/m2 versus referent group BMI <25 kg/m2
Crude 0.68 1.29 0.77
(0.50–0.94) (0.83–2.01) (0.55–1.09)
Socio-demographic adjusted† 0.49 0.78 0.52
(0.31–0.80) (0.39–1.55) (0.31–0.88)
Socio-demographic and clinical characteristic adjusted†† 0.47 0.75 0.35
(0.28–0.79) (0.35–1.63) (0.19–0.65)
†Adjusted for age, gender, race/ethnicity, marital status, education, employment status, income, health insurance, prescription drug insurance, and depression.
††Also adjusted for physical and mental health component scores, KOOS quality of life, WOMAC pain scale, weight at 25 years of age, hip replacement, history of
knee surgery, complaints of pain in multiple joints, OARSI severity scale, isometric strength/chair stands, and 20-meter walk.
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and reduced quality of life relative to persons with
BMI < 25 kg/m2. Despite a greater disease burden among
persons with BMI ≥ 25 kg/m2, we observed less CAM
use and greater conventional medication use relative to
those with BMI < 25 kg/m2. Our study was consistent
with general population studies in that use of individual
CAM modalities were less common in those with higher
BMI levels, albeit differences were modest [13]. Chiro-
practic use did not differ substantially by levels of BMI,
which was not consistent with studies showing less
chiropractic use among obese persons [29]. Considering
all individual CAM modalities, CAM use, either alone or
in conjunction with conventional medications, was less
common among persons with higher BMI levels. We
acknowledge that the clinical relevance of some of the
observed differences is unclear.
The correlates of CAM use differed by BMI level for
some, but not all factors. Women were more likely to
report use of CAM for knee OA than men and quality
of life was inversely associated with CAM use. Age of at
least 65 years was associated with CAM use only among
those with BMI ≥ 35 kg/m2. Black participants tended to
have lower odds of CAM use relative to white participants
among those with BMI between 25 and <30 kg/m2. This
association was not evident among other BMI levels. Our
finding that black participants had reduced odds of use of
CAM therapies than white participants was consistent
with some previous studies [30]. The reasons for racial
differences in CAM use are likely multifactorial, including
different access to health care and socioeconomic posi-
tioning. In our study, black participants had less favorable
socioeconomic positioning relative to white participants.
Residual confounding from socioeconomic status may
partially explain the inverse association. The reasons
for inconsistent association between race and CAM use
across BMI levels are unclear. Among persons with
BMI < 25 kg/m2, depression was inversely associated with
CAM use. We are unable to evaluate the extent to which
these findings are consistent with the literature because, to
our knowledge, no BMI level-specific correlates of CAM
use have been published.
Given there is no cure for OA, the clinical implications
of these findings must be considered. The use of CAM
to slow disease progression is not supported by research,
yet symptom relief among OA patients has been
reported with glucosamine [11] and acupuncture [12].
Obesity is a modifiable risk factor for the development
and treatment of knee pain [4]. Indeed, evidence from
Table 6 Correlates of CAM use among participants with radiographic-confirmed knee OA by BMI level
BMI ≥ 35 kg/m2 BMI between 30
and <35 kg/m2
BMI between 25
and <30 kg/m2
BMI < 25 kg/m2
(n = 364) (n = 804) (n = 1,042) (n = 465)
Odds ratios (95% Confidence intervals)a
Age≥ 65 years 2.79 (1.53-5.09) 1.29 (0.89-1.86) 1.01 (0.73-1.39) 1.22 (0.72-2.06)
Women 1.85 (1.08-3.15) 1.56 (1.11-2.17) 1.66 (1.25-2.21) 3.27 (2.03-5.27)
Race/ethnicity
Black 0.87 (0.51-1.48) 0.84 (0.57-1.25) 0.36 (0.23-0.58) 1.06 (0.42-2.71)
Latino 1.04 (0.13-8.13) 1.73 (0.24-12.34) 0.98 (0.33-2.97) 1.53 (0.30-7.68)
Other 0.20 (0.02-2.14) 1.69 (0.57-5.00) 1.48 (0.54-4.07) 2.35 (0.63-8.81)
Non-hispanic white 1.0 1.0 1.0 1.0
Education
≥College graduate 0.96 (0.49-1.87) 1.84 (1.20-2.82) 1.71 (1.14-2.56) 1.58 (0.80-3.13)
Some college 1.00 (0.52-1.91) 1.54 (0.97-2.43) 1.43 (0.91-2.24) 1.37 (0.63-2.96)
High school or less 1.0 1.0 1.0 1.0
Employment status 2.21 (1.26-3.88) 1.08 (0.75-1.55) 0.83 (0.61-1.13) 1.66 (1.01-2.73)
Depression 1.28 (0.66-2.50) 0.89 (0.52-1.52) 0.95 (0.55-1.64) 0.34 (0.14-0.81)
KOOS–QOLb 0.70 (0.53-0.91) 0.55 (0.45-0.66) 0.66 (0.57-0.78) 0.62 (0.48-0.80)
Multi-joint osteoarthritis 1.36 (0.79-2.33) 1.64 (1.17-2.30) 1.25 (0.94-1.68) 1.96 (1.24-3.11)
Isometric strength/chair stands (seconds)b 0.92 (0.71-1.19) 0.78 (0.66-0.93) 1.06 (0.91-1.23) 0.95 (0.74-1.21)
OARSIc Grade 3 (severe) 1.87 (0.92-3.79) 1.28 (0.79-2.06) 1.60 (1.07-2.39) 2.49 (1.26-4.91)
Grade 1–2 (narrowed) 1.27 (0.73-2.22) 1.08 (0.74-1.56) 1.15 (0.84-1.58) 1.17 (0.73-1.86)
Grade 0 (normal) 1.0 1.0 1.0 1.0
aModels stratified by obesity levels. bOdds ratios are per one standard deviation change in KOOS-QOL scale and chair stand test. cX-ray evidence of joint
space narrowing.
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trials [5-7] suggests that intensive exercise and weight
loss interventions result in improved pain and physical
function measures. However, the beneficial effects of
weight loss may be challenged by joint damage and
chronic pain from OA, which cause muscle atrophy,
decreased mobility, poor balance, and eventual physical
disability [4]. Some researchers have suggested that
adoption of weight loss strategies may be hampered by
pain, and that intensive treatment of pain resulting from
knee OA may improve exercise capacity and quality of
life [4].
The reasons why use of the treatment options is less
among persons with higher BMI levels are likely multi-
factorial, and may include differences in patient prefer-
ence, knowledge, and access to CAM. As the OAI did
not collect such information, we were unable to explore
the extent to which these factors explained observed
differences. Reports show CAM users in general pursue
generally healthy lifestyles [31], but use of CAM for
weight loss remains relatively low [32]. The latter finding
may suggest that persons with higher BMI levels may be
reluctant to use CAM in general, rather than reluctant
to use CAM specifically for OA symptom relief.
This study has several important limitations to con-
sider. The data shown are cross-sectional. The temporal
sequence of symptoms and treatment cannot be deter-
mined from this design. Data regarding symptoms and
treatment are based on self-report and may have intro-
duced bias. However, the information regarding conven-
tional medications and CAM therapies are based on
either a 30-day or 6-month recall. We believe this type
of misclassification is likely minimal and non-differential
with respect to BMI levels. Thus, if any distortions were
introduced, they would have attenuated the observed
associations. We are unable to comment on the extent
to which patterns of CAM use by BMI levels indicate
overuse of CAM by persons with lower BMI level or
underuse of CAM by persons with higher BMI levels.
Conclusion
Our study suggests that despite increased burden of dis-
ease, overweight and obese patients with radiographically-
confirmed knee OA are using CAM therapies less often
than those with lower BMI levels, but use of conventional
medications are more common in overweight and obese
patients. Overweight and obese adults may be less likely
to use effective CAM therapies relative to persons with
BMI < 25 mg/k2. Further research is needed to improve
our understanding of the role of CAM in the treatment of
knee OA among overweight and obese persons.
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